Skip to main content

Cardio/Pulmonary

QD Clinic: Rapidly progressive RA ILD - or not? Dr. Richard Conway, a rheumatologist in Dublin, Ireland, discusses whether this case shows rapidly progressing RA-ILD, or not, as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month of September 2025. https://t.co/YC8XFiqZmd
Dr. John Cush @RheumNow( View Tweet )
Rheumatoid Arthritis ILD Complications https://t.co/gAZCGTwHLB https://t.co/qcMmDuxXYx
Dr. John Cush @RheumNow( View Tweet )
Abatacept and Methotrexate may Lower Risk of Interstitial Lung Disease in RA A post hoc, pooled analysis of of rheumatoid arthritis (RA) clinical trials shows those received abatacept had a lower rate of Interstitial lung disease (ILD). https://t.co/3AISriCUeC https://t.co/nN03e4ZBDU
Dr. John Cush @RheumNow( View Tweet )
🌐 ILD Treatment Guidelines – LIVE Webinar 📅 Sept 9 (TOMORROW!) | ⏰ 7PM EST An expert panel reviews ACR & EULAR guidance and looks ahead at emerging therapies. Speakers: Drs. Sindhu Johnson, Anna-Maria Hoffmann-Vold, Scott Matson & Jack Cush, Moderator https://t.co/iQj8OstJDU https://t.co/WsN5vntKhH
Dr. John Cush @RheumNow( View Tweet )
Methotrexate significantly lowers Systolic BP Australian researchers have shown that methotrexate (MTX) has another secondary, beneficial effect by significantly lowering systolic blood pressure, and contributes to its well docuented cardioprotive effecs. https://t.co/HDnDWahuul
Dr. John Cush @RheumNow( View Tweet )

Addressing Disparities and Unequal Burdens in ILD

Interstitial lung diseases (ILDs) represent a complex spectrum of conditions that share one  unifying truth: they are almost always serious, progressive, and life-altering. But for many patients,  the burden of disease does not fall evenly. We are increasingly learning that where you

Read Article
Study of 607 systemic sclerosis (SSc) pts finds Pulm arterial HTN (PAH) in 77 (12.7%). While early immunosuppression didnt reduce odds of PAH (OR 0.74, p=0.495), early mycophenolate was protective(OR 0.12; p=0.048). Only HCQ use signif. improved survival (HR 0.04; p= 0.004). https://t.co/DbsJVZ16Zd
Dr. John Cush @RheumNow( View Tweet )
Lung Cancer in Rheumatoid Arthritis and Interstitial Lung Disease A matched cohort study from the Veterans Health Administration shows that RA patients have a >50% increased risk of lung cancer, a 3-fold higher risk of lung cancer in RA-ILD. https://t.co/Gjn2M2CNAO https://t.co/DPgDQsCWK9
Dr. John Cush @RheumNow( View Tweet )
Combined Therapy in Rheumatoid Arthritis Interstitial Lung Disease RA-ILD is a major therapeutic evidence gap in treatment, affecting 8% of patients. It was often under-diagnosed, leading to more severe cases and inflated mortality rates. Despite advancements, RA-ILD, https://t.co/sSzMvDUMf5
Dr. John Cush @RheumNow( View Tweet )
Retrospective Korean study of #RA & ILD pts (n 151) - ILD duration & UIP pattern significantly affected prognosis. 62% were non-smokers, DAS28=4.9, UIP in 60%. @4 years, ILD progressed in 58%; mortality=21%. MTX did not affect progression or mortality. https://t.co/1XNcWsAuea https://t.co/QLod6uj2Dj
Dr. John Cush @RheumNow( View Tweet )
🌐 ILD Treatment Guidelines – LIVE Webinar 📅 Sept 9 | ⏰ 7PM EST An expert panel reviews ACR & EULAR guidance and looks ahead at emerging therapies. Speakers: Drs. Sindhu Johnson, Anna-Maria Hoffmann-Vold, Scott Matson & Jack Cush, Moderator https://t.co/2F3sOjqHtr #ILD https://t.co/KaVL1pUdCh
Dr. John Cush @RheumNow( View Tweet )
Anti-MDA5 DM is assoc w/ rapidly progr ILD & mortality risk. 26 MD5+ DM pts (age 56.6 yrs; 7/26 male) Sxs: Gottrón’s (81%), ILD (73%), periungual erythema (69%), heliotrope (61%), V-sign (42%), arthritis (42%), weakness (38%), mechanic’s (35%), Raynaud’s (19%). 7/19 RP-ILD died https://t.co/WFwavo32rB
Dr. John Cush @RheumNow( View Tweet )
QD Clinic: Be Careful What You Look For Dr. Bryant England, University of Nebraska, presents this QD Clinic, as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month of September 2025. https://t.co/avxw86CGqu https://t.co/5SH3p05Rlf
Dr. John Cush @RheumNow( View Tweet )
EULAR & European Respiratory Society have published clinical practice guidelines for ILD assoc w/ connective tissue diseases (SSc, RA, SjD, IIM, SLE, MCTD). 2 publications included Dz specific ILD management algorithms; use of Hi Res CT over Lung Bx; ILD risk factors

Dr. John Cush @RheumNow( View Tweet )

Multimorbidity predicts flares in rheumatoid arthritis

A study from Olmstead county and the Mayo Clinic shows that multimorbidity  and social factors predict higher rheumatoid arthritis (RA) flares and lower remission rates.

Read Article

September to Remember (9.5.2025)

Dr. Jack Cush reviews the news and journal reports from RheumNow. This week - unemployment, diagnosing Sjogren's and a lot of ILD.

Read Article
Lung Cancer in Rheumatoid Arthritis and Interstitial Lung Disease A matched cohort study from the Veterans Health Administration shows that RA patients have a >50% increased risk of lung cancer, a 3-fold higher risk of lung cancer in RA-ILD. https://t.co/Gjn2M2CNAO https://t.co/F231nz57NY
Dr. John Cush @RheumNow( View Tweet )
Retrospective French Health Data System Immune Checkpt inhibitor (ICI) study. Of 172,363 ICI-Rx adult pts, ICI myotoxicities at 6 months ranged from 0.7% -0.9%. ICI myocarditis & myositis incidence was 0.3%- 0.6%, co-occurring in ∼13–23%. ICI myotoxicity- 1-mo fatality was https://t.co/kOGKM8lC0H
Dr. John Cush @RheumNow( View Tweet )
Connective tissue disease associated with interstitial lung disease (CTD-ILD) market is estimated to be $5.9 Billion USD in 2024 and is projected to grow to 9.3 billion, driven by increase in autoimmune Dz, adoption of biologics, ongoing clinical anti-fibrotic trials https://t.co/UqshQgNOau
Dr. John Cush @RheumNow( View Tweet )

Rheumatoid Arthritis ILD Complications

I'm a pulmonologist at the University of Kansas in Kansas City, and I'm excited to talk about one of my favorite topics: treatment complications in rheumatoid arthritis- associated interstitial lung disease or RA-ILD. One of the reasons I think this is a pressing and important topic is what we'

Read Article
Combined Therapy in Rheumatoid Arthritis Interstitial Lung Disease RA-ILD is a major therapeutic evidence gap in treatment, affecting 8% of patients. It was often under-diagnosed, leading to more severe cases and inflated mortality rates. Despite advancements, RA-ILD, https://t.co/Q8mMxtBgZZ
Dr. John Cush @RheumNow( View Tweet )

Abatacept and Methotrexate may Lower Risk of Interstitial Lung Disease in RA

A post hoc, pooled analysis of of rheumatoid arthritis (RA) clinical trials shows those received abatacept had a lower rate of Interstitial lung disease (ILD).

Read Article
Retrospective Korean study of #RA & ILD pts (n 151) - ILD duration & UIP pattern significantly affected prognosis. 62% were non-smokers, DAS28=4.9, UIP in 60%. @4 years, ILD progressed in 58%; mortality=21%. MTX did not affect progression or mortality. https://t.co/1XNcWsAuea https://t.co/hsUWi27OtQ
Dr. John Cush @RheumNow( View Tweet )
Biomarkers in ILD Join Elena K. Joerns, MD, as she highlights key insights on the role of biomarkers in ILD. Sponsored By: Boehringer Ingelheim. https://t.co/Mxg9P50m7C #ILD #Rheumatology https://t.co/tQUvwHD5cX
Dr. John Cush @RheumNow( View Tweet )
September is Pulmonary Fibrosis Awareness month. PF & ILD affect more than 250,000 Americans. The Pulmonary Fibrosis Foundation (PFF), will lead a nationwide campaign to raise awareness https://t.co/BYKeLcFP2U https://t.co/746CyLCT0z
Dr. John Cush @RheumNow( View Tweet )
×